ElectronRx Launches PurpleDx: A Revolutionary Cardiopulmonary Assessment App at CES 2025
ElectronRx, a leading digital medicine and biomarker company focused on pulmonary innovation, is set to launch purpleDx, a groundbreaking cardiopulmonary assessment app, at CES 2025. The app, built to medical device standards, promises to transform the way chronic respiratory disease (CRD) patients manage their health.
Empowering Patients and Clinicians
PurpleDx empowers CRD patients to monitor their lung function at home using their smartphones. By detecting and tracking digital biomarkers, patients gain valuable insights into their respiratory health. Clinicians benefit from real-time data provided through the app’s clinical dashboard, enabling them to customize treatment plans and optimize patient outcomes.
Tackling a Global Health Challenge
Chronic respiratory diseases are a leading cause of death worldwide. ElectronRx’s innovative technology aims to address this pressing issue by harnessing the power of digital biomarkers and wearable technology. PurpleDx targets a range of pulmonary conditions, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary hypertension.
Innovative Technology for Precise Monitoring
PurpleDx leverages the sensors in smartphones to capture physiological data, such as heart rate, respiratory rate, and tidal volume. This information is then transformed into actionable clinical biomarkers, providing healthcare providers with a comprehensive picture of a patient’s respiratory health. The real-time data allows for remote patient monitoring, reducing the need for frequent hospital visits and streamlining healthcare delivery.
A Collaborative Approach
Developed in partnership with respiratory clinics and the European pulmonary hypertension association (PHA Europe), purpleDx reflects a collaborative effort to improve the lives of patients living with CRD. ElectronRx’s commitment to innovation ensures that purpleDx remains at the forefront of technological advancements in pulmonary care.
Integrating digital biomarker monitoring with prescribed medications embodies a revolutionary approach to healthcare management. Our purpleDx technology transforms a mobile phone into a powerful tool that will not only enable patients to measure and quantify lung health but share these invaluable and potentially life-saving insights with their healthcare providers. This will empower them to manage chronic diseases more effectively and tailor treatments for individuals, leading to enhanced therapeutic outcomes.
We’re incorporating the latest clinical insights and data into purpleDx to ensure our platform remains at the forefront of technological innovation and continues to drive advancements in the management and treatment of CRDs worldwide.
We are incredibly grateful to all of our collaborators, particularly the patients, for their support and look forward to demonstrating electronRx’s purpleDx technology at CES next month.”
Dr Bipin Patel, CEO and Founder, electronRx
Discover the Future of Pulmonary Care
Experience the transformative potential of purpleDx at CES 2025. Learn how this innovative app is empowering patients and physicians to work together towards better respiratory health.